- Email: [email protected]
5470759 Anti-glycated hemoglobin monoclonal antibody and method for measuring glycated hemoglobin
PATENT ABSTRACTS
233
5470720
5470759
HIV ANTIBODY ASSAYS COMPRISING P24-GP41 CHIMERIC ANTIGENS
ANTI-GLYCATED HEMOGLOBIN MONOCLONAL ANTIBODY AND METHOD FOR MEASURING GLYCATED HEMOGLOBIN
Helting Torsten B; Drevin Hakan; Nunn Michael F La Jolla, CA, UNITED STATES assigned to Pharmacia Genetic Engineering Inc The present invention relates to a DNA segment encoding a recombinant HIV p24 protein or HIV p24-gp41 fusion protein and a recombinant DNA (rDNA) molecule capable of expressing either protein. Cells transformed with the rDNA, methods for producing the fusion protein and diagnostic methods and systems using the fusion protein are also described.
5470734 RECOMBINANT HERPES VIRUS OF TURKEYS AND LIVE VECTOR VACCINES DERIVED THEREOF Sondermeijer Paulus J A; Claessens Johannes A J; Mockett Albert P A Boxmeer, NETHERLANDS assigned to Akzo Nobel NV The present invention is concerned with a recombinant Herpesvirus of Turkeys (HVT), containing a heterologous gene incorporated into an insertion region of the genome of HVT. The invention also relates to a vector vaccine comprising such a recombinant HVT which expresses a heterologous antigenic polypeptide and induces an adequate immune response on infection of an appropriate host animal.
Sugiyama Masarn; Uchida Yoshiak; Kurano Yoshihir; Tanaka Aiko; Tanimoto Tetsuj Tokyo, JAPAN assigned to Fujirebio Inc A method for measuring glycated hemoglobin is disclosed, which comprises contacting a with an sample anti-hemoglobin antibody being bound to a solid phase, adding thereto an anti-glycated hemoglobin antibody, and anti-glycated then measuring the hemoglobin antibody bound to the solid phase via glycated hemoglobin and the anti-hemoglobin antibody. A method for measuring glycated hemoglobin is further disclosed, which comprises mixing a sample with particles on which an anti-glycated hemoglobin antibody is bound to cause immunoagglutination reaction. A method for measuring glycated hemoglobin is furthermore disclosed, which comprises mixing a sample with a solution containing a monoclonal antibody specific for glycated hemoglobin, and then measuring the change in the turbidity of the resulting mixture. A method is disclosed measuring glycated for hemoglobin which comprises mixing a sample with unsensitized latex particles and an anti-glycated hemoglobin antibody, to cause immunoagglutination reaction. There is disclosed a method for measuring glycated hemoglobin which comprises mixing a sample with unsensitized latex particles and particles on which an anti-glycated hemoglobin antibody is bound, to cause immunoagglutination reaction. Still furthermore, an anti-glycated hemoglobin monoclonal antibody having a high specificity for human glycated
PATENT ABSTRACTS
234
hemoglobin is disclosed. 5470824 METHOD TO TREAT KAPOSI’S SARCOMA Miles Steven; Stevens Ronald H; Martinez Otoniel; Kishimoto Tadamits; Klashman David J Sherman Oaks, CA, UNITED STATES assigned to The Regents of the University of California Substances or agents which diminish the level of IL-6 or its activity in Kaposi’s sarcoma-derived cells are useful agents in the treatment of Kaposi’s sarcoma. In particular, substances which inhibit the expression of the gene encoding IL-6 or its receptor, or which interfere with the activity of these substances, are useful in the treatment of this condition. In particular, antibodies immunoreactive with these proteins, oligomers which interfere with the production of these materials, or substances which interfere with the activity of other proteins, DNAs or RNAs that regulate the production and activity of IL-6 are thus useful.
responses, parasitic and helminthic infections, hypersensitivity reactions and certain types of leukocytic leukemias.
5470826 SINGLE CHAIN PROTEINS WITH FHS SUPPRESSING ACTIVITY ISOLATED FROM FOLLICULAR FLUID AND USES THEREOF De Kretser David; Burger Henry; Hearn Milton T; Mime-Robertson David M; Wettenhall Richard E H; McLachlan Robert; De Vos Fiona Surrey Hills, AUSTRALIA assigned to Biotechnology Australia Pty Ltd; Monash University Monash Medical Centre St Vincents Institute of Medical Research
Polypeptides exhibiting an inhibitory action over follitropin are disclosed. These polypeptides are designated follitropin suppressing proteins, or FSP’s, and range in size from 30 to 60 kD as determined by SDS-PAGE. Uses for FSP’s, including regulation of fertility and as immunogens, are disclosed.
5470825
5470827
BASOPHIL GRANULE PROTEINS
METHOD OF PRODUCING ITURIN A AND ANTIFUNGAL AGENT FOR PROFOUND MYCOSIS
Scott Randy W; Gleich Gerald J; Wilde Craig Sunnyvale, CA, UNITED STATES assigned to Incyte Pharmaceuticals Inc Several natural polypeptides (basophil granule proteins, BGP ) derived from the cytoplasmic granules of human basophils, and modified forms thereof, are described. These polypeptides, the DNA which encodes them and antibodies which recognize them, are useful as diagnostics for, and treatments for, pathologies involving inflammatory and IgE-mediated
Tanaka Yasushi; Tojo Takashi; Uchida Kazuhik; Uno Jun; Uchida Yasushi; Shida Osamu Chiba, JAPAN assigned to Higeta Shoyu Co Ltd The present invention is a method of producing iturin A, in which cells of Bacillus amyloliquefaciens are incubated and iturin A is collected from the culture. It also relates to an antifungal agent for profound mycosis, containing iturin A as
233
5470720
5470759
HIV ANTIBODY ASSAYS COMPRISING P24-GP41 CHIMERIC ANTIGENS
ANTI-GLYCATED HEMOGLOBIN MONOCLONAL ANTIBODY AND METHOD FOR MEASURING GLYCATED HEMOGLOBIN
Helting Torsten B; Drevin Hakan; Nunn Michael F La Jolla, CA, UNITED STATES assigned to Pharmacia Genetic Engineering Inc The present invention relates to a DNA segment encoding a recombinant HIV p24 protein or HIV p24-gp41 fusion protein and a recombinant DNA (rDNA) molecule capable of expressing either protein. Cells transformed with the rDNA, methods for producing the fusion protein and diagnostic methods and systems using the fusion protein are also described.
5470734 RECOMBINANT HERPES VIRUS OF TURKEYS AND LIVE VECTOR VACCINES DERIVED THEREOF Sondermeijer Paulus J A; Claessens Johannes A J; Mockett Albert P A Boxmeer, NETHERLANDS assigned to Akzo Nobel NV The present invention is concerned with a recombinant Herpesvirus of Turkeys (HVT), containing a heterologous gene incorporated into an insertion region of the genome of HVT. The invention also relates to a vector vaccine comprising such a recombinant HVT which expresses a heterologous antigenic polypeptide and induces an adequate immune response on infection of an appropriate host animal.
Sugiyama Masarn; Uchida Yoshiak; Kurano Yoshihir; Tanaka Aiko; Tanimoto Tetsuj Tokyo, JAPAN assigned to Fujirebio Inc A method for measuring glycated hemoglobin is disclosed, which comprises contacting a with an sample anti-hemoglobin antibody being bound to a solid phase, adding thereto an anti-glycated hemoglobin antibody, and anti-glycated then measuring the hemoglobin antibody bound to the solid phase via glycated hemoglobin and the anti-hemoglobin antibody. A method for measuring glycated hemoglobin is further disclosed, which comprises mixing a sample with particles on which an anti-glycated hemoglobin antibody is bound to cause immunoagglutination reaction. A method for measuring glycated hemoglobin is furthermore disclosed, which comprises mixing a sample with a solution containing a monoclonal antibody specific for glycated hemoglobin, and then measuring the change in the turbidity of the resulting mixture. A method is disclosed measuring glycated for hemoglobin which comprises mixing a sample with unsensitized latex particles and an anti-glycated hemoglobin antibody, to cause immunoagglutination reaction. There is disclosed a method for measuring glycated hemoglobin which comprises mixing a sample with unsensitized latex particles and particles on which an anti-glycated hemoglobin antibody is bound, to cause immunoagglutination reaction. Still furthermore, an anti-glycated hemoglobin monoclonal antibody having a high specificity for human glycated
PATENT ABSTRACTS
234
hemoglobin is disclosed. 5470824 METHOD TO TREAT KAPOSI’S SARCOMA Miles Steven; Stevens Ronald H; Martinez Otoniel; Kishimoto Tadamits; Klashman David J Sherman Oaks, CA, UNITED STATES assigned to The Regents of the University of California Substances or agents which diminish the level of IL-6 or its activity in Kaposi’s sarcoma-derived cells are useful agents in the treatment of Kaposi’s sarcoma. In particular, substances which inhibit the expression of the gene encoding IL-6 or its receptor, or which interfere with the activity of these substances, are useful in the treatment of this condition. In particular, antibodies immunoreactive with these proteins, oligomers which interfere with the production of these materials, or substances which interfere with the activity of other proteins, DNAs or RNAs that regulate the production and activity of IL-6 are thus useful.
responses, parasitic and helminthic infections, hypersensitivity reactions and certain types of leukocytic leukemias.
5470826 SINGLE CHAIN PROTEINS WITH FHS SUPPRESSING ACTIVITY ISOLATED FROM FOLLICULAR FLUID AND USES THEREOF De Kretser David; Burger Henry; Hearn Milton T; Mime-Robertson David M; Wettenhall Richard E H; McLachlan Robert; De Vos Fiona Surrey Hills, AUSTRALIA assigned to Biotechnology Australia Pty Ltd; Monash University Monash Medical Centre St Vincents Institute of Medical Research
Polypeptides exhibiting an inhibitory action over follitropin are disclosed. These polypeptides are designated follitropin suppressing proteins, or FSP’s, and range in size from 30 to 60 kD as determined by SDS-PAGE. Uses for FSP’s, including regulation of fertility and as immunogens, are disclosed.
5470825
5470827
BASOPHIL GRANULE PROTEINS
METHOD OF PRODUCING ITURIN A AND ANTIFUNGAL AGENT FOR PROFOUND MYCOSIS
Scott Randy W; Gleich Gerald J; Wilde Craig Sunnyvale, CA, UNITED STATES assigned to Incyte Pharmaceuticals Inc Several natural polypeptides (basophil granule proteins, BGP ) derived from the cytoplasmic granules of human basophils, and modified forms thereof, are described. These polypeptides, the DNA which encodes them and antibodies which recognize them, are useful as diagnostics for, and treatments for, pathologies involving inflammatory and IgE-mediated
Tanaka Yasushi; Tojo Takashi; Uchida Kazuhik; Uno Jun; Uchida Yasushi; Shida Osamu Chiba, JAPAN assigned to Higeta Shoyu Co Ltd The present invention is a method of producing iturin A, in which cells of Bacillus amyloliquefaciens are incubated and iturin A is collected from the culture. It also relates to an antifungal agent for profound mycosis, containing iturin A as